Answers are grounded in this paper and cite their sources.
Ixekizumab is a high-affinity IgG4 monoclonal humanized antibody indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy. We describe the case of a 54-female patient with HLAB27+ spondyloarthritis. The patient experienced immediate severe dyspnea, skin erythema and flushing after ixekizumab administration. Our 8-step protocol desensitization to ixekizumab was safe and effective enabling the patient to maintain the best therapeutical option for her.
No takes yet. Share an insight, caveat, or question.
Gutiérrez et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: